Pantethine Shows Proof-of-Concept Efficacy as Adjunct Psoriasis Therapy

A 12-week trial in 24 psoriasis patients found that pantethine, a vitamin B5 derivative sold as a cholesterol-lowering supplement, improved symptoms when added to standard topical calcipotriene/betamethasone ointment. The investigator-initiated study, run by researchers at the State Key Laboratory of Biomedical Analysis in Beijing, paired the small clinical trial with mouse experiments and cellular work published October 27, 2026 in the Journal of Experimental Medicine (DOI: 10.1084/jem.20252558).

Half of the 24 patients took pantethine tablets on top of the combination ointment; the other half received the topical alone. The pantethine arm showed symptomatic improvements, most pronounced in participants who entered the trial with elevated blood cholesterol. The authors call the results encouraging but preliminary — the trial cannot establish pantethine as a standalone treatment, nor confirm that the clinical benefit ran through the same mechanism seen in the lab.

What drives the inflammation?

The research centers on dendritic cells, the immune sentinels that present foreign substances to T cells and release recruiting chemical signals. When they turn hyperactive, they sustain the inflammation behind psoriasis and other autoimmune diseases.

The Beijing team found unusually high levels of enzymes called Vanins in dendritic cells from patients with psoriasis and several other autoimmune conditions. Vanins convert pantethine into vitamin B5, a nutrient central to cellular energy production. Rampant Vanin activity depletes pantethine, which pushes cholesterol production inside dendritic cells and triggers excessive immune activation — what the authors term the Vanin-pantethine-cholesterol axis.

"Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression," said Wei-Na Zhang, a researcher at the State Key Laboratory of Biomedical Analysis in Beijing. "But therapeutic strategies targeting metabolism in inflammatory diseases remain underexplored."

What did the experiments show?

The researchers tested the axis at three levels:

• Knocking down Vanin levels in dendritic cells made them less active and less able to stimulate T cells.
• A drug inhibiting Vanins prevented psoriasis from developing in mice.
• Replenishing pantethine cut cholesterol accumulation inside dendritic cells, suppressed their activation and alleviated psoriasis symptoms in mice.

"We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the up-regulation of Vanins," Zhang said.

What does the trial mean for practice?

Pantethine has been on supplement shelves for years because it inhibits cholesterol synthesis. The new work argues its grip on cholesterol metabolism also shapes immune responses — but the 24-patient trial stops well short of mechanistic proof in humans.

"Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation," Zhang said. "Overall, our study uncovers the Vanin-pantethine-cholesterol axis as a key metabolic pathway governing dendritic cell activation and provides a foundation for therapeutic strategies targeting several dendritic cell–mediated autoimmune diseases."

The senior author list spans 21 researchers, led by first author Ai-Ping Cao and corresponding authors including Qing Xia and Wei-Na Zhang. No PASI or other validated severity endpoints appear in the released findings, and the trial lacked a formal placebo supplement arm — clinicians should read the result as a feasibility signal, not a treatment recommendation.

Larger controlled trials with standardized psoriasis scoring will be needed before pantethine can move from the supplement aisle toward an evidence-based adjunct role in plaque psoriasis.